Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma
Brief Summary: The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg
C: Arm Label: GSK573719 15.6 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 31.25 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 125 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 15.6 mcg twice-daily; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 31.25 mcg twice daily; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Intervention Type: DRUG; Name: GSK573719 Active treatment or Placebo; Assigned to Arm(s): GSK573719 125 mcg, GSK573719 15.6 mcg, GSK573719 15.6 mcg twice-daily, GSK573719 250 mcg, GSK573719 31.25 mcg, GSK573719 31.25 mcg twice daily, GSK573719 62.5 mcg, Matched Placebo | Intervention Type: PROCEDURE; Name: GSK573719 (Sub-group cohort); Assigned to Arm(s): GSK573719 125 mcg, GSK573719 15.6 mcg, GSK573719 15.6 mcg twice-daily, GSK573719 250 mcg, GSK573719 31.25 mcg, GSK573719 31.25 mcg twice daily, GSK573719 62.5 mcg, Matched Placebo | Intervention Type: DRUG; Name: Salbutamol/Albuterol; Assigned to Arm(s): GSK573719 125 mcg, GSK573719 15.6 mcg, GSK573719 15.6 mcg twice-daily, GSK573719 250 mcg, GSK573719 31.25 mcg, GSK573719 31.25 mcg twice daily, GSK573719 62.5 mcg, Matched Placebo
D: Arm Label: Fp MDPI 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 110 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: Fp MDPI 200 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 220 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 100/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 250/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 200/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 500/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Intervention Type: DRUG; Name: Fp MDPI; Assigned to Arm(s): Fp MDPI 100 mcg, Fp MDPI 200 mcg | Intervention Type: DRUG; Name: FS MDPI; Assigned to Arm(s): FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg | Intervention Type: DRUG; Name: FLOVENT HFA; Assigned to Arm(s): FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg | Intervention Type: DRUG; Name: ADVAIR DISKUS; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg | Intervention Type: DRUG; Name: albuterol/salbutamol HFA; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg, FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg, FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg, Fp MDPI 100 mcg, Fp MDPI 200 mcg

Answer: B